For Industry

Public Meeting on Patient-Focused Drug Development for Sarcopenia

On April 6, 2017, FDA is conducting a public meeting on Patient-Focused Drug Development (PFDD) for Sarcopenia. FDA is interested in obtaining patient perspectives on the on the impact of sarcopenia on daily life and patient views on treatment approaches.


April 6, 2017


1:00 p.m. - 5:00 p.m.


Tommy Douglas Conference Center
10000 New Hampshire Ave.
Silver Spring, MD 20903


To register for this meeting, visit: Patient-Focused Drug Development Public Meeting for Sarcopenia Event Britedisclaimer icon website.

Registration to attend the meeting must be received by April 6, 2017.

Public Docket:

In addition to providing input at the public meeting, stakeholders are invited to provide their perspectives on the discussion questions through the public docket. The docket closes on June 6, 2017.

Page Last Updated: 10/25/2017
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English